Dupilumab and QoL in Moderate-to-severe Atopic Dermatitis Dupilumab and QoL in Moderate-to-severe Atopic Dermatitis

Does dupilumab, a recently approved biologic, improve clinical response and quality of life in adults with moderate-to-severe atopic dermatitis?The British Journal of Dermatology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news